WuXi wants to regain client confidence amid claims of IP transfer to Chinese authorities
WuXi AppTec said it has “unwavering commitment” to protecting its customer’s intellectual property, in the face of allegations it passed a US client’s information to Chinese authorities.
Although the Biosecure Act “may create short-term uncertainty” for the wider biopharma industry, the Shanghai-headquartered company “remains steadfast in ‘doing the right thing and doing it right,’” WuXi AppTec CEO Ge Li said in the company’s first-quarter earnings press release Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
